IP Library Granted Patent US 9,687,496
Granted Patent B2
US 9,687,496 · App. 14/626,490 · Granted Jun 27, 2017

Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties

Inventors: Torbjörn Bäckström (Umea, SE); Anders Carlsson (Stockholm, SE)
Assignee: ASARINA PHARMA AB
A61K31/57A61K9/10A61K9/107A61K31/575A61K47/14A61K47/28A61K47/44A61K9/0019A61K9/0034A61K9/0043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,687,496
App. No.
14/626,490
Granted
Jun 27, 2017
Kind
B2
Abstract

It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.

Claims (14)

1. A pharmaceutical oil composition, consisting of:

3-beta-hydroxy-5-alpha-pregnan-20-one;

cholesterol or an ester thereof; and

a mixture of acylglycerols, wherein the mixture of acylglycerols is a medium-chain acylglycerol.

2. The pharmaceutical oil composition according to claim 1 wherein the mixture of acylglycerols has a total combined percentage of (i) fatty acids with eight carbon atoms and (ii) fatty acids with ten carbon atoms of at least 95%.

3. The pharmaceutical oil composition according to claim 1 , wherein the 3-beta-hydroxy-5-alpha-pregnan-20-one is essentially dissolved.

4. The pharmaceutical oil composition according to claim 1 , wherein the 3-beta-hydroxy-5-alpha-pregnan-20-one is in the form of an oil suspension consisting of some of the 3-beta-hydroxy-5-alpha-pregnan-20-one in the form of suspended particles and some of the 3-beta-hydroxy-5-alpha-pregnan-20-one dissolved in the oil composition.

5. The pharmaceutical oil composition according to claim 1 , wherein the medium-chain acylglycerol consists of from about 50% to about 65% of monoacylglycerols, about 25% to about 35% of diacylglycerols, less than about 5% of triacylglycerols and less than about 2.5% of glycerol.

6. A pharmaceutical oil composition for parenteral administration according to claim 1 .

7. A pharmaceutical oil composition for vaginal administration according to claim 1 .

8. A method of terminating steroid induced anesthesia, comprising: administering the pharmaceutical composition according to claim 1 to a subject in need thereof.

9. The pharmaceutical oil composition according to claim 1 , wherein said medium-chain acylglycerol is a mixture of acylglycerols wherein the total combined percentage of fatty acids with 8 carbon atoms and 10 carbon atoms is at least 95%.

10. The pharmaceutical oil composition according to claim 1 , wherein said medium-chain acylglycerol comprises at least about 95% triacylglycerols.

11. The pharmaceutical oil composition according to claim 1 , wherein said medium-chain acylglycerol is a mixture of acylglycerols wherein the total combined percentage of fatty acids with 8 carbon atoms and 10 carbon atoms is at least 95% and said medium-chain acylglycerol comprises at least about 95% triacylglycerols.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2025
From: ASARINA PHARMA AB
To: RELMADA THERAPEUTICS, INC.
Reel/Frame 070543/0439 →
CHANGE OF NAME Recorded May 19, 2017
From: UMECRINE MOOD AB
To: ASARINA PHARMA AB
Reel/Frame 042506/0648 →
Priority Claims (1)
SE 1050029-6 · Jan 14, 2010 · national
Continuity (3)
Division 13522081
Provisional Application 61295027 · Jan 14, 2010
Related Publication 20150164914A1 · Jun 18, 2015